|
1
|
Cramer DW and Finn OJ: Epidemiologic
perspective on immune-surveillance in cancer. Curr Opin Immunol.
23:265–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kruyt FAE and Schuringa JJ: Apoptosis and
cancer stem cells: implications for apoptosis targeted therapy.
Biochem Pharmacol. 80:423–430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaux DL and Silke J: IAPs, RINGs and
ubiquitylation. Nat Rev Mol Cell Biol. 6:287–297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li XF, Gong RY, Wang M, et al: Sorafenib
down-regulates c-IAP expression post-transcriptionally in hepatic
carcinoma cells to suppress apoptosis. Biochem Biophys Res Commun.
418:531–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ndubaku C, Varfolomeev E, Wang L, et al:
Antagonism of c-IAP and XIAP proteins is required for efficient
induction of cell death by small-molecule IAP antagonists. ACS Chem
Biol. 4:557–566. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Berger R, Jennewein C, Marschall V, et al:
NF-kappaB is required for Smac mimetic-mediated sensitization of
glioblastoma cells for gamma-irradiation-induced apoptosis. Mol
Cancer Ther. 10:1867–1875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ashhab Y, Alian A, Polliack A, Panet A and
Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis
gene with different biological properties and tissue distribution
pattern. FEBS Lett. 495:56–60. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wagener N, Crnkovic-Mertens I, Vetter C,
et al: Expression of inhibitor of apoptosis protein Livin in renal
cell carcinoma and non-tumorous adult kidney. Br J Cancer.
97:1271–1276. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
El-Mesallamy HO, Hegab HM and Kamal AM:
Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in
acute leukemia in adults: correlation with prognostic factors and
outcome. Leuk Res. 35:1616–1622. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hariu H, Hirohashi Y, Torigoe T, et al:
Aberrant expression and potency as a cancer immunotherapy target of
inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Clin Cancer Res. 11:1000–1009. 2005.PubMed/NCBI
|
|
12
|
Chen N, Gong J, Chen X, et al: Caspases
and inhibitor of apoptosis proteins in cutaneous and mucosal
melanoma: expression profile and clinicopathologic significance.
Hum Pathol. 40:950–956. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang TS, Ding QQ, Guo RH, et al:
Expression of livin in gastric cancer and induction of apoptosis in
SGC-7901 cells by shRNA-mediated silencing of livin gene. Biomed
Pharmacother. 64:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Crnkovic-Mertens I, Wagener N, Semzow J,
et al: Targeted inhibition of Livin resensitizes renal cancer cells
towards apoptosis. Cell Mol Life Sci. 64:1137–1144. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Crnkovic-Mertens I, Hoppe-Seyler F and
Butz K: Induction of apoptosis in tumor cells by siRNA-mediated
silencing of the livin/ML-IAP/KIAP gene. Oncogene. 22:8330–8336.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yagihashi A, Asanuma K, Tsuji N, et al:
Detection of anti-livin antibody in gastrointestinal cancer
patients. Clin Chem. 49:1206–1208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yagihashi A, Asanuma K, Kobayashi D, et
al: Detection of autoantibodies to livin and survivin in Sera from
lung cancer patients. Lung Cancer. 48:217–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Engelhardt JJ, Boldajipour B, Beemiller P,
et al: Marginating dendritic cells of the tumor microenvironment
cross-present tumor antigens and stably engage tumor-specific T
cells. Cancer Cell. 21:402–417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Steinman RM and Banchereau J: Taking
dendritic cells into medicine. Nature. 449:419–426. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Atanackovic D, Luetkens T, Kloth B, et al:
Cancer-testis antigen expression and its epigenetic modulation in
acute myeloid leukemia. Am J Hematol. 86:918–922. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seo MJ, Kim GR, Son YM, et al:
Interactions of dendritic cells with cancer cells and modulation of
surface molecules affect functional properties of CD8+ T
cells. Mol Immunol. 48:1744–1752. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kakimi K, Nakajima J and Wada H: Active
specific immunotherapy and cell-transfer therapy for the treatment
of non-small cell lung cancer. Lung Cancer. 65:1–8. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brenner MK and Heslop HE: Adoptive T cell
therapy of cancer. Curr Opin Immunol. 22:251–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han P, Hodge G, Story C and Xu X:
Phenotypic analysis of functional T-lymphocyte subtypes and natural
killer cells in human cord blood: relevance to umbilical cord blood
transplantation. Br J Haematol. 89:733–740. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Germenis AE and Karanikas V: Cord blood as
a source of non-senescent lymphocytes for tumor immunotherapy. J
Reprod Immunol. 85:47–50. 2010.PubMed/NCBI
|
|
26
|
Brown JA and Boussiotis VA: Umbilical cord
blood transplantation: basic biology and clinical challenges to
immune reconstitution. Clin Immunol. 127:286–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brunstein CG, Gutman JA, Weisdorf DJ, et
al: Allogeneic hematopoietic cell transplantation for hematologic
malignancy: relative risks and benefits of double umbilical cord
blood. Blood. 116:4693–4699. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie J, Xiong L, Tao X, et al: Antitumor
effects of murine bone marrow-derived dendritic cells infected with
xenogeneic livin alpha recombinant adenoviral vectors against Lewis
lung carcinoma. Lung Cancer. 68:338–345. 2010. View Article : Google Scholar
|
|
29
|
Antonia SJ, Mirza N, Fricke I, et al:
Combination of p53 cancer vaccine with chemotherapy in patients
with extensive stage small cell lung cancer. Clin Cancer Res.
12:878–887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anderson RJ and Schneider J: Plasmid DNA
and viral vector-based vaccines for the treatment of cancer.
Vaccine. 25:B24–B34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ljunggren HG and Malmberg KJ: Prospects
for the use of NK cells in immunotherapy of human cancer. Nat Rev
Immunol. 7:329–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guiducci C, Vicari AP, Sangaletti S,
Trinchieri G and Colombo MP: Redirecting in vivo elicited tumor
infiltrating macrophages and dendritic cells towards tumor
rejection. Cancer Res. 65:3437–3446. 2005.PubMed/NCBI
|
|
33
|
Xu RL, Tang Y, Ogburn PL, et al:
Implication of delayed TNF-alpha exposure on dendritic cell
maturation and expansion from cryopreserved cord blood
CD34+ hematopoietic progenitors. J Immunol Methods.
293:169–182. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Safdar A, Decker WK, Li S, et al: De novo
T-lymphocyte responses against baculovirus-derived recombinant
influenzavirus hemagglutinin generated by a naive umbilical cord
blood model of dendritic cell vaccination. Vaccine. 27:1479–1484.
2009. View Article : Google Scholar
|
|
35
|
Mainali ES and Tew JG: Dexamethasone
selectively inhibits differentiation of cord blood stem cell
derived-dendritic cell (DC) precursors into immature DCs. Cell
Immunol. 232:127–136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gansuvd B, Hagihara M, Higuchi A, et al:
Umbilical cord blood dendritic cells are a rich source of soluble
HLA-DR: synergistic effect of exosomes and dendritic cells on
autologous or allogeneic T-Cell proliferation. Hum Immunol.
64:427–439. 2003.PubMed/NCBI
|
|
37
|
Tang XD, Wan Y, Chen L, et al:
H-2Kb-restricted CTL epitopes from mouse heparanase elicit an
antitumor immune response in vivo. Cancer Res. 68:1529–1537. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oku M, Okumi M, Sahara H, et al: Porcine
CFSE mixed lymphocyte reaction and PKH-26 cell-mediated lympholysis
assays. Transpl Immunol. 20:78–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo F, Song X, Zhang Y and Chu Y: Low-dose
curcumin leads to the inhibition of tumor growth via enhancing
CTL-mediated antitumor immunity. Int Immunopharmacol. 11:1234–1240.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsieh CH, Huang YC, Tsai TH and Chen YJ:
Cantharidin modulates development of human monocyte-derived
dendritic cells. Toxicol In Vitro. 25:1740–1747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cholujova D, Jakubikova J, Kubes M, et al:
Comparative study of four fluorescent probes for evaluation of
natural killer cell cytotoxicity assays. Immunobiology.
213:629–640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Disis ML, Bernhard H and Jaffee EM: Use of
tumour-responsive T cells as cancer treatment. Lancet. 373:673–683.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seki N, Brooks AD, Carter CR, et al:
Tumor-specific CTL kill murine renal cancer cells using both
perforin and Fas ligand-mediated lysis in vitro, but cause tumor
regression in vivo in the absence of perforin. J Immunol.
168:3484–3492. 2002. View Article : Google Scholar
|
|
44
|
Caldwell SA, Ryan MH, McDuffie E and
Abrams SI: The Fas/Fas ligand pathway is important for optimal
tumor regression in a mouse model of CTL adoptive immunotherapy of
experimental CMS4 lung metastases. J Immunol. 171:2402–2412. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Begley J and Ribas A: Targeted therapies
to improve tumor immunotherapy. Clin Cancer Res. 14:4385–4391.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Smith SG, Patel PM, Selby PJ and Jackson
AM: The response of human dendritic cells to recombinant
adenovirus, recombinant Mycobacterium bovis Bacillus Calmette
Guerin and biolistic methods of antigen delivery: different
induction of contact-dependant and soluble signals. Immunol Lett.
76:79–88. 2001. View Article : Google Scholar
|
|
47
|
Yee C: Adoptive T cell therapy: addressing
challenges in cancer immunotherapy. J Transl Med. 3:172005.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xing W, Wu S, Yuan X, et al: The
anti-tumor effect of human monocyte-derived dendritic cells loaded
with HSV-TK/GCV induced dying cells. Cell Immunol. 254:135–141.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wojas-Krawczyk K, Krawczyk P, Buczkowski
J, et al: Immunotherapy of lung adenocarcinoma patient with
Peptide-pulsed dendritic cells: a case report. Arch Immunol Ther
Exp. 60:69–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Prasad S, Cody V, Saucier-Sawyer JK, et
al: Polymer nanoparticles containing tumor lysates as antigen
delivery vehicles for dendritic cell-based antitumor immunotherapy.
Nanomedicine. 7:1–10. 2011. View Article : Google Scholar
|
|
51
|
Lucas S and Coulie PG: About human tumor
antigens to be used in immunotherapy. Semin Immunol. 20:301–307.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Beebe M, Qin MS, Moi M, et al: Formulation
and characterization of a ten-peptide single-vial vaccine, EP-2101,
designed to induce cytotoxic T-lymphocyte responses for cancer
immunotherapy. Hum Vaccin. 4:210–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Spiotto MT, Fu YX and Schreiber H: Tumor
immunity meets autoimmunity: antigen levels and dendritic cell
maturation. Curr Opin Immunol. 15:725–730. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yang JY, Cao DY, Liu WC, Zhang HM, Teng ZH
and Ren J: Dendritic cell generated from CD34+
hematopoietic progenitors can be transfected with adenovirus
containing gene of HBsAg and induce antigen-specific cytotoxic T
cell responses. Cell Immunol. 240:14–21. 2006.PubMed/NCBI
|
|
55
|
Dianzani U, Chiocchetti A and Ramenghi U:
Role of inherited defects decreasing Fas function in autoimmunity.
Life Sci. 72:2803–2824. 2003. View Article : Google Scholar : PubMed/NCBI
|
